Gabor Forgacs
Gabor Forgacs, Ph.D.
George Vineyard Chair in Biophysics, the University of Missouri-Columbia,
Chanderna-Stirkey Chair in Theoretical Physics, Clarkson University,
Scientific Director, the Shipley Innovation Center, Clarkson University.


Dr. Gabor Forgacs is a theoretical physicist turned biophysicist turned bioengineer turned innovator and entrepreneur. His academic affiliations include the George Vineyard Chair in Biophysics at the University of Missouri-Columbia and the Chanderna-Stirkey Chair in Theoretical Physics at Clarkson University, where he is also the Scientific Director of the Shipley Innovation Center. He is the scientific founder of Organovo, Inc. and Modern Meadow, Inc. and serves as the Chief Scientific Officer of the latter. He was trained as a physicist at the Roland Eotvos University, Budapest, Hungary. He also has a degree in biology.

His research interests and contributions span from topics in theoretical physics to physical mechanisms in early embryonic development. He is the author of over 200 scientific publications and 5 books, in particular the co-author of the celebrated text in the field, "Biological Physics of the Developing Embryo" that discusses physical mechanisms that guide embryonic development. He applies these mechanisms to build organ structures using bioprinting, a technology he pioneered. Such structures are already used for drug development and testing. The technology has also been adapted to engineer consumer products of animal origin such as leather and meat in environmentally friendly and ethically conscious manner.

Dr. Forgacs has been recognized by numerous prizes and awards. In particular, he is a member of the National Academy of Innovators and was named as one of the "100 most innovative people in business in 2010" by FastCompany.


Present and near-future academic and commercial applications of bioprinting

Engineering of 3D tissues and organs has seen spectacular progress in recent years. The technologies of 3D printing and organ-on-the chip are already providing invaluable tools and structures for numerous applications. In basic research these structures are used as models to study early developmental processes, cellular interactions and disease in near-physiological conditions. In pharmaceutics they provide novel tools for drug development and toxicity essays. Therapeutic applications are in the pipeline. In the near future these applications are expected to further improve and expand. In today's drug toxicity studies the engineered construct is typically subjected to new candidate drugs and metabolic functions are assessed by secreted metabolites in the surrounding culture medium. In tomorrow's essays implanted Lab-on-a-Chip devices will be used for the in situ monitoring of metabolic and functional properties of engineered tissues and organ structures. Today, human clinical trials are preceded by animal trials. Tomorrow, animals will be replaced by model organisms representing combinations of bioprinted tissues. We will discuss such and similar near-future applications and conclude with presenting our views on the longer-term promise of bioprinting.

  • DAYS
Key Dates

  Abstract continue accepting
Deadline for early registration
  September 15, 2017